» Articles » PMID: 30254843

Immune Mechanisms in the Different Phases of Acute Tubular Necrosis

Overview
Specialty Nephrology
Date 2018 Sep 27
PMID 30254843
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Acute kidney injury is a clinical syndrome that can be caused by numerous diseases including acute tubular necrosis (ATN). ATN evolves in several phases, all of which are accompanied by different immune mechanisms as an integral component of the disease process. In the early injury phase, regulated necrosis, damage-associated molecular patterns, danger sensing, and neutrophil-driven sterile inflammation enhance each other and contribute to the crescendo of necroinflammation and tissue injury. In the late injury phase, renal dysfunction becomes clinically apparent, and M1 macrophage-driven sterile inflammation contributes to ongoing necroinflammation and renal dysfunction. In the recovery phase, M2-macrophages and anti-inflammatory mediators counteract the inflammatory process, and compensatory remnant nephron and cell hypertrophy promote an early functional recovery of renal function, while some tubules are still badly injured and necrotic material is removed by phagocytes. The resolution of inflammation is required to promote the intrinsic regenerative capacity of tubules to replace at least some of the necrotic cells. Several immune mechanisms support this wound-healing-like re-epithelialization process. Similar to wound healing, this response is associated with mesenchymal healing, with a profound immune cell contribution in terms of collagen production and secretion of profibrotic mediators. These and numerous other factors determine whether, in the chronic phase, persistent loss of nephrons and hyperfunction of remnant nephrons will result in stable renal function or progress to decline of renal function such as progressive chronic kidney disease.

Citing Articles

Pathogenesis and management of renal fibrosis induced by unilateral ureteral obstruction.

Nan Q, Piao S, Jin J, Chung B, Yang C, Li C Kidney Res Clin Pract. 2024; 43(5):586-599.

PMID: 38325866 PMC: 11467363. DOI: 10.23876/j.krcp.23.156.


NETosis: an emerging therapeutic target in renal diseases.

Juha M, Molnar A, Jakus Z, Ledo N Front Immunol. 2023; 14:1253667.

PMID: 37744367 PMC: 10514582. DOI: 10.3389/fimmu.2023.1253667.


IKK1 aggravates ischemia-reperfusion kidney injury by promoting the differentiation of effector T cells.

Song N, Xu Y, Paust H, Panzer U, de Las Noriega M, Guo L Cell Mol Life Sci. 2023; 80(5):125.

PMID: 37074502 PMC: 10115737. DOI: 10.1007/s00018-023-04763-2.


Deficiency of mindin reduces renal injury after ischemia reperfusion.

Bai T, Wang X, Qin C, Yang K, Duan Z, Cao Z Mol Med. 2022; 28(1):152.

PMID: 36510147 PMC: 9743537. DOI: 10.1186/s10020-022-00578-2.


Role of T cells in ischemic acute kidney injury and repair.

Lee K, Jang H Korean J Intern Med. 2022; 37(3):534-550.

PMID: 35508946 PMC: 9082442. DOI: 10.3904/kjim.2021.526.


References
1.
Darisipudi M, Thomasova D, Mulay S, Brech D, Noessner E, Liapis H . Uromodulin triggers IL-1β-dependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol. 2012; 23(11):1783-9. PMC: 3482735. DOI: 10.1681/ASN.2012040338. View

2.
Ortiz A, Sanchez-Nino M, Izquierdo M, Martin-Cleary C, Garcia-Bermejo L, Moreno J . Translational value of animal models of kidney failure. Eur J Pharmacol. 2015; 759:205-20. DOI: 10.1016/j.ejphar.2015.03.026. View

3.
Linkermann A, Heller J, Prokai A, Weinberg J, De Zen F, Himmerkus N . The RIP1-kinase inhibitor necrostatin-1 prevents osmotic nephrosis and contrast-induced AKI in mice. J Am Soc Nephrol. 2013; 24(10):1545-57. PMC: 3785275. DOI: 10.1681/ASN.2012121169. View

4.
Martinez F, Gordon S . The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. PMC: 3944738. DOI: 10.12703/P6-13. View

5.
Kim J, Kim M, Kim S, Nguyen T, Kim E, Lee S . Dendritic Cell Dysfunction in Patients with End-stage Renal Disease. Immune Netw. 2017; 17(3):152-162. PMC: 5484645. DOI: 10.4110/in.2017.17.3.152. View